1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of 1-methyl-D-tryptophan in
treating patients with metastatic or refractory solid tumors that cannot be removed by
surgery. Biological therapies, such as 1-methyl-D-tryptophan, may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth and by stimulating the immune
system.